TREATMENT WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (BDMARDS) AT A MELBOURNE PUBLIC HOSPITAL. RETENTION ON INITIAL BDMARD AT 36 MONTHS, AND PATTERNS OF CORTICOSTEROID USE BEFORE AND AFTER BDMARD COMMENCEMENT

Pourhadi, H; Foote, A

INTERNAL MEDICINE JOURNAL, 2022; 52 (): 38